They target HER2, CD20, VEGF, BRAF, IL6, the hedgehog pathway and lung fibrosis.
Explore below everything you need to know: booklets and forms, efficacy and safety information and useful resources.
For a full list of our products visit roche.co.nz
Actemra is an anti-IL6 receptor antibody for rheumatoid arthritis, systemic juvenile idiopathic arthritis, and polyarticular juvenile idiopathic arthritis.
Avastin is a VEGF inhibitor used to treat a wide range of cancers.
Erivedge is a hedgehog pathway inhibitor for adults with advanced basal cell carcinoma.
Esbriet is an oral medicine for patients with idiopathic pulmonary fibrosis (IPF)
GAZYVA is an anti-CD20 therapy for first line chronic lymphocytic leukaemia.
Herceptin targets HER2 in early and metastatic breast cancer, as well as gastric cancer.
Kadcyla is an antibody-drug conjugate for HER2-positive metastatic breast cancer.
MabThera is an anti-CD20 therapy for rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis.
MabThera targets the CD20 antigen to treat non-Hodgkin lymphoma and chronic lymphocytic leukaemia.
OCREVUS is a monoclonal antibody that selectively targets CD20-expressing B-cells in Multiple Sclerosis
Perjeta is a HER2 dimerisation inhibitor for neoadjuvant (eBC) and advanced breast cancer.
Zelboraf is a BRAF kinase inhibitor for metastatic melanoma.